Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 4;9(2):137. doi: 10.3390/antiox9020137

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Post-treatment with erinacine A weakened the MPTP-induced neurotoxin and movement deficit. (A) Erinacine A intraperitoneally postadministered in the MPTP-treated animals after 5 days. An animal behavior test was performed 5 days after erinacine A was administered and then the animals were scarified by decapitation. Accelerating rotarod tests for the animals with MPP⁺ or MPP⁺ and erinacine A were performed as indicated after 1 day of training. Quantified data for the elapsed time during the six test trials is shown. (B) Immunohistochemistry (IHC) staining for the global IHC intensity of all dopaminergic neurons’ protein tyrosine hydroxylase in the substantia nigra of the animals. (C) Quantitative immunohistochemical protein tyrosine hydroxylase was evaluated according to the average integrated optical density (AIOD). The positive stained area was evaluated from three randomly selected observation fields for each brain section. Data are expressed as mean ± S.D. (n = 6/group); * p < 0.05, as compared to the control group, magnification ×400; * p < 0.01, as compared to the control group; # p < 0.01, as compared to the MPP⁺-treated group.